210 related articles for article (PubMed ID: 22069174)
21. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
22. [Gastrointestinal stromal tumor].
Nishida T; Ohmori T; Matsuda H
Gan To Kagaku Ryoho; 2004 Mar; 31(3):331-6. PubMed ID: 15045935
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
Nilsson B; Sjölund K; Kindblom LG; Meis-Kindblom JM; Bümming P; Nilsson O; Andersson J; Ahlman H
Br J Cancer; 2007 Jun; 96(11):1656-8. PubMed ID: 17533389
[TBL] [Abstract][Full Text] [Related]
24. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal stromal tumor: 5 years later.
van der Zwan SM; DeMatteo RP
Cancer; 2005 Nov; 104(9):1781-8. PubMed ID: 16136600
[TBL] [Abstract][Full Text] [Related]
26. Practical management of imatinib in gastrointestinal stromal tumors.
Barnes T; Reinke D
Clin J Oncol Nurs; 2011 Oct; 15(5):533-45. PubMed ID: 21951740
[TBL] [Abstract][Full Text] [Related]
27. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
Pan ZZ; Wu XJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
[TBL] [Abstract][Full Text] [Related]
28. Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?
Hohenberger P
Nat Clin Pract Oncol; 2008 May; 5(5):240-1. PubMed ID: 18349856
[No Abstract] [Full Text] [Related]
29. Current clinical management of gastrointestinal stromal tumors.
Tosoni A; Nicolardi L; Brandes AA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
[TBL] [Abstract][Full Text] [Related]
30. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
Gronchi A
Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
[TBL] [Abstract][Full Text] [Related]
31. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
Láng I; Hitre E
Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
[TBL] [Abstract][Full Text] [Related]
32. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
35. Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour.
Prescrire Int; 2011 Feb; 20(113):38. PubMed ID: 21488587
[No Abstract] [Full Text] [Related]
36. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Eisenberg BL; Judson I
Ann Surg Oncol; 2004 May; 11(5):465-75. PubMed ID: 15123459
[TBL] [Abstract][Full Text] [Related]
37. Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
Quintero CB; Cubedo R
Anticancer Drugs; 2012 Jun; 23 Suppl():S1-2. PubMed ID: 22739664
[No Abstract] [Full Text] [Related]
38. Imatinib in gastrointestinal stromal tumors.
Bakshi CA; Jain RA; Sastry PS; Sainani AR; Advani SH
J Assoc Physicians India; 2004 May; 52():403-9. PubMed ID: 15656032
[TBL] [Abstract][Full Text] [Related]
39. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
Romeo S; Debiec-Rychter M; Van Glabbeke M; Van Paassen H; Comite P; Van Eijk R; Oosting J; Verweij J; Terrier P; Schneider U; Sciot R; Blay JY; Hogendoorn PC;
Clin Cancer Res; 2009 Jun; 15(12):4191-8. PubMed ID: 19509155
[TBL] [Abstract][Full Text] [Related]
40. [Curative resection for bulky gastrointestinal stromal tumor with conversion therapy by imatinib].
Nishimura T; Sakata K; Maeda Y; Nagashima Y; Okada T; Nakamura M; Setoguchi M
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2202-4. PubMed ID: 22202330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
